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Background: Surgical site infections (SSIs) constitute a major clinical problem in terms of morbidity, mortality,
duration of hospital stay, and overall costs. The bacterial pathogens implicated most frequently are Streptococcus
pyogenes (S. pyogenes) and Staphylococcus aureus (S. aureus). The incidence of methicillin-resistant S. aureus (MRSA)
SSIs is increasing significantly. Since these infections have a significant impact on hospital budgets and patients’
health, their diagnosis must be anticipated and therapy improved. The first step should be to evaluate risk factors
for MRSA SSIs.
Methods: Through a literature review, we identified possible major and minor risk factors for, and protective factors
against MRSA SSIs. We then submitted statements on these factors to 228 Italian surgeons to determine, using the
Delphi method, the degree of consensus regarding their importance. The consensus was rated as positive if >80%
of the voters agreed with a statement and as negative if >80% of the voters disagreed. In other cases, no
consensus was reached.
Results: There was positive consensus that sepsis, >2 weeks of hospitalization, age >75 years, colonization by
MRSA, and diabetes were major risk factors for MRSA SSIs. Other possible major risk factors, on which a consensus
was not reached, e.g., prior antibiotic use, were considered minor risk factors. Other minor risk factors were
identified. An adequate antibiotic prophylaxis, laparoscopic technique, and infection committee surveillance were
considered protective factors against MRSA SSIs. All these factors might be used to build predictive criteria for
identifying SSI due to MRSA.
Conclusions: In order to help to recognize and thus promptly initiate an adequate antibiotic therapy for MRSA SSIs,
we designed a gradation of risk and protective factors. Validation, ideally prospective, of this score is now required.
In the case of a SSI, if the risk that the infection is caused by MRSA is high, empiric antibiotic therapy should be
started after debriding the wound and collecting material for culture.
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Surgical site infections: background
The Food and Drug Administration (FDA) recently
proposed a new classification of skin and soft tissue in-
fections namely acute bacterial skin and skin structure
infections (ABSSSIs) which comprise erysipelas, cellulitis,
major subcutaneous abscesses, and wound infections,
including surgical site infections (SSIs). An ABSSSI is a
bacterial infection of the skin with a lesion area of at least
75 cm2, measured by redness, edema, or induration [1].
ABSSSIs constitute a significant burden for the healthcare
system and their incidence is increasing. They have
become a challenging clinical problem associated with
high direct and indirect costs. Bacterial pathogens that
commonly cause ABSSSIs include S. pyogenes and S.
aureus, including a large number of methicillin-resistant
S. aureus (MRSA) strains.
Given the associated morbidity, mortality, length of
hospital stay, and overall direct and indirect costs, SSIs
represent a significant problem [2–4]. Moreover, MRSA
infections can have an even greater impact on hospital
budgets and on patients’ health, since they are more se-
vere, may lead to longer hospital stays, and are associ-
ated with higher mortality.
Despite progresses in prevention, SSIs remain one of
the most common adverse events in hospitals, account-
ing for 11 to 26% of all healthcare-associated infections
[5]. In Italy, the rate of SSIs ranged from 5.4 to 12.8%,
although recent studies have shown a reduction to 5%,
[6, 7]. Surgical patients can develop several types of
post-operative infection, with wound infections being
the most common. The specific surgical procedures for
each specialty are associated to different percentages of
SSIs [8]. These complications add 10–20% additional
extra costs to the total hospital bill [9].
In the USA, for any given type of operation, the devel-
opment of a wound infection will approximately double
the cost of hospitalization. These infections lead to
80,000 deaths per year and are associated with an annual
treatment cost of US$2 billion [10]. A similar scenario
has been found in Italy, where nosocomial infections
occur in 500,000 out of 8,000,000 hospital admissions
per year [11].
SSIs caused by S. aureus may be life threatening (esti-
mated mortality rate 5%) and account for more than two
extra weeks of hospitalization and around US$50,000
extra cost [12]. Rates of MRSA infection are increasing
dramatically, and there is an urgent need to reduce hospi-
talizations and costs and implement more effective out-
patient management and treatment strategies. Since cost
containment and cost-efficient patient management are
top priorities today, for the whole healthcare system, many
hospitalized patients with SSIs could be safely treated, as
outpatients, with current options of intravenous antibiotictherapy. This would reduce costs for hospitalization and
could also improve patients’ outcome and satisfaction.
Diagnosis-related groups and the incidence of surgical
site infections
The exact incidence of SSIs is difficult to determine. In
fact, the Diagnosis-Related Group (DRG) system underes-
timates the rate of SSIs, due to a very early discharge of
surgical patients. Hospitals without a surveillance system
report infection rates of less than 5%. This figure probably
underestimates the problem, mostly because many SSIs
are diagnosed after the patient has been discharged from
hospital [8]. For example, Petrosillo et al. described that
SSIs occurred in 5.2% out of 4665 patients and that, while
148 SSIs (61.4%) were diagnosed during the patients’ stay
in hospital, 93 (38.6%) were recorded within 30 days after
discharge [13]. This is comparable to the 34.8% result
found in another Italian study on general surgery patients
reported by Fiorio et al. [14]. However, in another similar
surveillance study, higher post-discharge rates of SSI were
found [15]. Marchi et al. reported data on non-prosthetic
surgery from the Italian SSI surveillance program for the
period 2009 to 2011, based on 60,460 operations from 355
surgical wards: SSIs were observed in 1628 cases (2.6%),
with 60% of these being diagnosed on day 30 post-
discharge surveillance [16].
Thus, up to 60% of SSIs are diagnosed after discharge
from hospital, and this trend is increasing as the length
of post-operative hospital stay is getting shorter and the
number of 1-day surgery procedures is increasing [17].
According to current literature, active infection surveil-
lance is useful in reducing the incidence of SSIs through
surveillance-induced infection control efforts [18]. Opera-
tions performed in hospitals with at least 2 years of sur-
veillance showed a 29% lower risk of SSIs, confirming that
surveillance is a protective factor in preventing SSIs [16].
Classification of surgical site infections
The identification of SSIs involves interpretation of clin-
ical and laboratory findings. The Centers for Disease
Control and Prevention (CDC) National Nosocomial
Infections Surveillance (NNIS) system has developed
standardized surveillance criteria for defining SSIs [19].
Using these criteria, SSIs are classified as either inci-
sional or organ/space. Incisional SSIs are further divided
into those involving only skin and subcutaneous tissue
(superficial incisional SSIs) and those involving deeper
soft tissues of the incision (deep incisional SSIs). Organ/
space infections are not included in ABSSSIs.
Predominant pathogens in surgical site infections
According to the NNIS system reports, the most commonly
encountered pathogens in SSIs are Gram-positive cocci,
particularly Staphylococcus aureus (S. aureus), coagulase-
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pyogenes), and Enterococcus spp., followed by Escherichia
coli, Pseudomonas aeruginosa and Enterobacter spp. [20].
The source of pathogens is often the endogenous flora of
the patient’s skin, mucous membranes, or hollow viscera
[21]. Microorganisms of endogenous flora are usually aer-
obic Gram-positive cocci (e.g., staphylococci), but may
also include fecal flora (e.g., anaerobic bacteria and Gram-
negative aerobes) [22].
Exogenous sources of pathogens involved in SSIs
include surgical personnel (especially members of the
surgical team), the operating room environment (including
air), and all tools, instruments, and materials brought to
the sterile field. Exogenous flora consists primarily of
aerobes, especially Gram-positive organisms (e.g., staphylo-
cocci and streptococci) [23].
Besides S. aureus and CoNS, Staphylococcus epidermidis
may be responsible for severe infections following im-
plantation of any prosthesis in general surgery, cardiac
surgery, orthopedics, etc. Such infections may require
removal of the prosthesis.
Table 1 lists the more frequent pathogens, according
to surgical procedure.
Staphylococcus aureus in surgical site infections
S. aureus is consistently the leading cause of nosocomial
infections, including SSIs. The incidence of MRSA
strains is rising dramatically, and the amount of hospi-
talizations has more than doubled, in the past decade.Table 1 Most frequently encountered pathogens, according to the
Type of surgery




Ophthalmic (limited data; anterior segment resection, vitrectomy, and
scleral buckling)
Orthopedic (total joint replacement, closed fractures/use of nails, plates, othe
internal fixation device, functional repair without implant/device trauma)
Non-cardiac thoracic (lobectomy, pneumonectomy, wedge resection,










S. aureus Staphylococcus aureusRemarkably, MRSA is the main pathogen causing SSIs
in many academic and community hospitals [24]. This
represents a significant, independent risk factor for
adverse clinical and economic outcomes. Kirkland et al.
estimated that the excess hospital costs associated with
MRSA SSIs ranged from US$3089 to US$35,367 [3].
Engemann et al. found that, among surgical patients,
those with MRSA infections were hospitalized 5 days
longer than those with methicillin-sensitive S. aureus
(MSSA) infections [25]. Hospital charges for MRSA
patients were also US$62,908 greater than for patients
without an infection and US$40,000 greater than for
patients with MSSA infections.
Other studies support the findings that patients with
MRSA infections require more health-care resources than
patients with MSSA infections [26]. Weigelt et al. deter-
mined that the risk-adjusted attributable increase in
duration of hospitalization was approximately 1 day and,
in terms of costs for the hospitalization, over US$1000.
They also found that significant independent risk factors,
increasing costs, and time spent in hospital for SSIs due to
MRSA, included illness severity, transfer from another
healthcare facility, a previous hospital admission (30 days),
and other polymicrobial infections (p < 0.05) [27].
Methicillin-resistant Staphylococcus aureus
MRSA is a versatile and dangerous bacterial pathogen
that shows virulence, antibiotic resistance, and survival
fitness [28]. Selection pressure, exercised by broad-surgical procedure [8]
Likely pathogens
S. aureus, coagulase-negative staphylococci
S. aureus, coagulase-negative staphylococci
S. aureus, coagulase-negative staphylococci
S. aureus, coagulase-negative staphylococci
S. aureus, coagulase-negative staphylococci, streptococci,
Gram-negative bacilli
r S. aureus, coagulase-negative staphylococci, Gram-negative bacilli
S. aureus, coagulase-negative staphylococci, S. pneumoniae,
Gram-negative bacilli




Gram-negative bacilli, streptococci, oropharyngeal anaerobes
(e.g., peptostreptococci)
S. aureus, streptococci, oropharyngeal anaerobes
(e.g., peptostreptococci)
Gram-negative bacilli, enterococci, group B streptococci, anaerobes
Gram-negative bacilli
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through healthcare workers’ hands, facilitates its spread-
ing. Hence, profiles to identify patients at high risk of
MRSA carriage might improve prevention of MRSA in-
fections because MRSA carriers, without symptomatic
infection, are an important pathogen reservoir [29].
Efforts should be made to identify patients at risk of
colonization and subsequent infection by multi-drug-
resistant microorganisms such as MRSA, and to control
hospital-acquired SSIs. Remarkably, surveillance systems,
even without any specific intervention, have been associ-
ated with a reduction in SSIs [30]. Because all authors
do not recommend a universal rapid MRSA screening,
other methods to pick out patients at high risk of MRSA
colonization and subsequent SSIs could be very useful.
Harbart et al. found that age 75 years or older, previous
hospitalization (in the preceding 12 months), and recent
antibiotic therapy (in the preceding 6 months) were the
strongest risk factors for MRSA colonization in surgical
patients, then confirmed in a validation cohort [31].
Applying the Delphi method, we recently identified the
most common risk factors for colonization and/or infec-
tion by MRSA as being patient from a long-term care
facility, previous hospitalization (within the preceding
30 days), Charlson score >5, chronic obstructive pulmon-
ary disease and thoracic surgery, antibiotic therapy with
beta-lactams (especially cephalosporin and carbapenems)
and/or quinolones in the preceding 30 days, age 75 years
or older, current duration of hospital admission >16 days,
and prosthetic implant surgery. Furthermore, protective
factors were an adequate antibiotic prophylaxis, laparo-
scopic surgery, and the presence in the hospital of an
active surveillance program for infection control [8].Therapy for methicillin-resistant Staphylococcus aureus
Clinical MRSA isolates show a decreased susceptibility
or increased resistance to anti-MRSA drugs. Thus, treat-
ment of ABSSSIs is now challenged by toxicity, few oral
options, and greater need for hospitalization and its
associated costs [32].
The Infectious Diseases Society of America (IDSA)
recommended beta-lactam or clindamycin for mild/
moderate non-purulent ABSSSIs, and vancomycin plus
piperacillin/tazobactam for severe non-purulent ABSS-
SIs treatments [33]. In purulent ABSSSIs, doxycycline
or trimethoprim/sulfamethoxazole should cover MRSA
for moderate cases and vancomycin, daptomycin, linez-
olid, or ceftaroline in severe cases. Antimicrobials avail-
able in Italy for treating ABSSSIs with activity against
MRSA and other resistant Gram-positive pathogens
include vancomycin, teicoplanin, daptomycin, linezolid,
and ceftaroline. Of these antimicrobials, only linezolid
is available in an oral formulation.Table 2 reports the main characteristics of anti-MRSA
drugs for SSIs. Some of these drugs have significant
potential toxicity (e.g., myopathy from daptomycin, renal
function impairment from vancomycin, bone marrow
suppression from linezolid) and drug interactions (e.g.,
linezolid and selective serotonin re-uptake inhibitors).
While doxycycline and trimethoprim/sulfamethoxazole
are active against MRSA, their activity against beta-
hemolytic streptococci is poor, limiting their use as
monotherapy for ABSSSIs.
Dalbavancin, a novel lipoglycopeptide antibiotic active
against both MSSA and MRSA, was approved by the FDA
in May 2014 and by the European Medicines Agency
(EMA) in February 2015 for the treatment of ABSSSIs
caused by susceptible Gram-positive organisms [34].
Several clinical trials have demonstrated its tolerability, effi-
cacy, and non-inferiority compared to standard therapy for
ABSSSIs. The DISCOVER 1 and DISCOVER 2 studies
showed that once-weekly intravenous dalbavancin was not
inferior to twice-daily intravenous vancomycin, followed by
oral linezolid for the treatment of ABSSSIs. Adverse events
were reported less frequently in patients treated with
dalbavancin, than in those treated with vancomycin-
linezolid [35]. Dalbavancin’s high-protein binding and
prolonged half-life allow for easily and consistently
attainable therapeutic levels. It has a well-established
activity against the Gram-positive organisms commonly
involved in superficial and deep SSIs, including MRSA
and other multidrug-resistant pathogens, and the MIC90
values for these organisms have remained stable over the
past decade.
Dalbavancin, as an anti-MRSA agent, displays advanta-
geous factors, such as bactericidal effect, full activity on
biofilm [36], which could be increased by combination
with rifampicin, lack of drug-drug interactions, lack of
renal toxicity, and no adverse events associated with an
early discharge from hospital, because of its prolonged
half-life. Indeed, the most unique feature of dalbavancin
is its once-weekly dosing, previously approved as a
1000 mg dose followed by 500 mg 1 week later, and then
the one-shot, single-dose of 1500 mg, recently approved
by the EMA [37].
The aim of this study was to create a score for the
early recognition of SSIs caused by MRSA in order to
facilitate the prompt initiation of adequate antibiotic
therapy.
Methods
After a systematic literature review on SSIs (randomized
clinical trials, case-control studies, recommendations
and case reports), we proposed some major and minor
risk factors, and protective factors, drawn from the
literature and identified in a previous work [8], to an
expert board of general and specialist surgeons.






Doses Adverse events Interactions Cost (for a
70 kg person)
Teicoplanin Bactericidal with low
MIC; time-dependent;
None
iv, im 7-10 mg/Kg once
daily, loading dose
Renal toxicity None €50-70/day
Vancomycin Bactericidal with low
MIC; time-dependent;
None
iv 1 g twice daily,
500 mg four times
a day






iv 4-6 mg/kg Myotoxicity Statins €80-120/day
Linezolid Bacteriostatic; time-
dependent; None







iv 50 mg twice daily;






iv 600 mg twice daily Rash None €96/day
Dalbavancin Bactericidal; concentration-
dependent; Yes
iv 1000 mg day 1, 500 mg





iv, oral 800/160 mg 3 times a day Anemia None €15/day
Rifampin Bactericidal; time-
dependent; Yes
iv, oral 600 mg once a day Liver toxicity Several €6/day
iv intravenous, im intramuscular, SSRIs selective serotonin re-uptake inhibitors
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The Delphi method is a widely used technique to define
standards, therapies, and care procedures based on the
opinions of groups of experts [38–40].
An algorithm method may be useful for identifying
patients without risk factors (high negative predictive
model) but may be less efficient at identifying the true
positives (low positive predictive value). With the Delphi
method, each participant expresses his or her opinion
anonymously, contributing to create the expert opinion
of the entire group. The participants are asked to re-
spond to a questionnaire, divided into statements, and
independently assign a score ranging from 1 (which cor-
responds to “maximum disagreement”) up to 5 (which
corresponds to “absolute agreement”).
We considered a positive consensus when more than
80% of the participants agree with the statement pro-
posed and negative consensus when >80% of the partici-
pants disagree with it. In other cases, a consensus was
not reached.
Here, 228 surgeons, members of the Italian Society
of Surgeons, were asked to find a possible consensus
on risk factors for MRSA, using the Delphi method
[38–40]. The questions, based on a review of the lit-
erature and our previous research, concerned major
and minor risk factors for and protective factors
against SSIs due to MRSA.Results
Having identified possible major and minor risk factors
for MRSA SSIs, as well as potential protective factors,
we determined the level of consensus regarding these
factors among a large group of Italian surgeons using
the Delphi method. Consensus was achieved when more
than 80% of the group agreed (positive consensus) or
disagreed (negative consensus) on a statement proposed.
Table 3 reports the submitted risk and protective fac-
tors with the rate of agreement. The questions were
rated as major and minor risk factors for SSIs due to
MRSA.
A positive consensus was reached on the fact that
sepsis, >2 weeks spent in hospital, age >75 years, and
colonization by MRSA were major risk factors for MRSA
SSIs (Table 4). The board also agreed that diabetes was a
minor risk factor for MRSA SSIs. Other possible risk fac-
tors, on which a consensus was not reached, i.e., antibiotic
use in the preceding year, ICU admission in the preceding
year, prosthetic surgery, admission to hospital or rehabilita-
tion facility within the preceding 6 months, obesity, steroids
and immunosuppressive treatment, renal insufficiency,
chronic obstructive pulmonary disease, and surgery lasting
more than 3 h, were considered minor risk factors. An
adequate antibiotic prophylaxis, laparoscopic technique,
and infection committee surveillance were considered
strong factors protecting against MRSA SSIs (Table 4).
Table 3 Risk factors for and protective factors against MRSA SSIs
with the level of agreement obtained by the Delphi method
Risk factors for SSIs due to MRSA Percentage of
consensus
Major risk factors for MRSA SSIs
Signs and severity of sepsis Consensus (>80%)
Colonization by MRSA Consensus (>80%)
Age > 75 years Consensus (>80%)
Duration of hospitalization > 2 weeks Consensus (>80%)
Previous treatment with antibiotics, from
30 days to 12 months
No consensus (<80%)
ICU admission in the previous 12 months No consensus (<80%)
Any prosthetic surgery No consensus (<80%)
Previous admission to hospital (6 months)
and/or rehabilitation structure
No consensus (<80%)
Minor risk factors for MRSA SSIs
Diabetes (HbA1c > 7%) Consensus (>80%)
Obesity (BMI > 30) No consensus (<80%)
Steroids and immunosuppressive treatment No consensus (<80%)
Previous hospital admission from 30 days
to 6 months
No consensus (<80%)
Renal insufficiency No consensus (<80%)
Chronic obstructive pulmonary disease No consensus (<80%)
Other antibiotic therapy from 30 days
to 6 months
No consensus (<80%)
Surgical operation lasting more than 3 h No consensus (<80%)
Protective factors for MRSA SSIs
Adequate antibiotic prophylaxis Consensus (>80%)
Laparoscopic technique Consensus (>80%)
Hospital with an Infection Surveillance
Committee
Consensus (>80%)
ICU intensive care unit, HbA1c, glycated hemoglobin, BMI body mass index
Table 4 Suggested score to assess the risk of MRSA SSIs
MRSA SSIs risk and protective factors
Sepsis signs and severity Major risk factor
Duration of hospitalization > 2 weeks Major risk factor
Age > 75 years Major risk factor
Colonization by MRSA Major risk factor
Diabetes (HbA1c > 7) Major risk factor
Procalcitonin dosage >3 mg/dl Minor risk factor
Previous admission in hospital (6 months)
and/or rehabilitation structure
Minor risk factor
Previous treatment with antibiotics, from
30 days to 12 months
Minor risk factor
ICU admission during the previous 12 months Minor risk factor
Any prosthetic surgery Minor risk factor
Obesity (BMI > 30) Minor risk factor
Steroids and immunosuppressive treatment Minor risk factor
Previous hospital admission from 30 days to
6 months
Minor risk factor
Renal insufficiency Minor risk factor
Chronic obstructive pulmonary disease Minor risk factor
Other antibiotic therapy from 30 days to
6 months
Minor risk factor
Surgical procedure lasting more than 3 h Minor risk factor
Adequate antibiotic prophylaxis Major protective factor
Laparoscopic technique Major protective factor
Hospital with an Infection Surveillance
Committee
Major protective factor
ICU intensive care unit, HbA1c glycated hemoglobin, BMI body mass index
Sganga et al. World Journal of Emergency Surgery  (2017) 12:25 Page 6 of 8These factors should be validated in prospective stud-
ies, for better identification of patients at higher risk of
developing MRSA SSIs or earlier identification of
patients who already have an SSI, due to MRSA. To
promptly start an appropriate, effective antibiotic ther-
apy promptly, we proposed to identify major and minor
risk and protective factors, to assess the risk of MRSA
SSIs, as shown in Table 4, we merged results from a
review of the literature and the Delphi consensus
results described here. We think that these factors
should be evaluated for predicting the need to start
antibiotic therapy, given the high risk of the patient
having a MRSA SSI.
Discussion
ABSSSIs have become a challenging clinical issue, asso-
ciated with high direct and indirect costs. SSIs are an
important subgroup of ABSSSIs and are associated with
high rates of morbidity. Among other pathogens, MRSAis prevalent in ABSSSIs and in SSIs. Indeed, the rates of
MRSA infection and related hospitalizations are increas-
ing dramatically and MRSA has emerged as the most
common cause of purulent infections. Besides, MRSA
infection is a risk factor for subsequent hospitalization
and death. In the management of surgical patients, it
could therefore be very important to recognize if there
are risk factors for the development of SSI caused by
MRSA.
Through a systematic review of the literature and the
consensus of 228 Italian surgeons, obtained by the
Delphi method, we made an effort to identify and quan-
tify the importance of risk factors for and protective fac-
tors against MRSA SSIs. Our primary aim was to
facilitate the early recognition of SSIs caused by MRSA,
which leads to promptly start an adequate antibiotic
therapy (Table 4). These risk and protective factors can
be rapidly validated in retrospective and/or perspective
studies, in order to have an instrument, for surgeons
and physicians, to identify patients with a suspected
MRSA SSI. However, our propositions are not an alter-
native to current, recommended measures of hygiene
and appropriate antibiotic prophylaxis.
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taking samples of the material obtained from the wound
for culture, empiric antibiotic therapy should be started,
especially if the risk of a MRSA infection is high. There is,
however, an urgent need to reduce hospitalization,
through the use of more effective outpatient treatment
strategies that can reduce costs and improve patients’ out-
comes and satisfaction. Because early discharge is almost
always recommended for surgical patients, dalbavancin
might be a beneficial addition to the therapeutic arma-
mentarium for the treatment of SSIs, since its use does
not prolong the time of the hospital stay. In fact, dalbavan-
cin, with its long half-life, can be administered also in the
case of programmed discharge of a patient.
Conclusions
SSIs due to MRSA are associated with considerable mor-
bidity and mortality, as well as being a heavy financial
burden on the healthcare system. Through a systematic
review of the literature and the consensus of 228 Italian
surgeons, obtained by the Delphi method, we suggest
major and minor risk and protective factors to facilitate
the early recognition of SSIs caused by MRSA in order
to promptly start an appropriate antibiotic therapy.
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